Overview

Blackrock Neurotech is the commercialization leader of Utah Array technology, which pioneered intracortical microelectrode recording in the early 2000s at the University of Utah. The company was formally incorporated in 2008 and has facilitated dozens of human implants across research and clinical settings, accumulating unmatched experience with penetrating electrode arrays.

Product and Technology

The MoveAgain device achieved FDA Breakthrough Device Designation in 2021, enabling accelerated clinical development. Blackrock maintains the gold standard for intracortical signal quality through the Utah Array’s 96-100 electrode configuration. The company is now developing Neuralace, a flexible electrode interface designed to reduce chronic scarring and improve long-term biocompatibility.

Funding and Scale

Blackrock has raised over $200 million in funding, including a significant $200 million investment from Tether in recent years. This capital injection enables expansion of manufacturing capacity and acceleration of next-generation device development.

Clinical Position

With the longest operational history of any commercial BCI company, Blackrock has established the regulatory framework and clinical partnerships that newer competitors now navigate. The company’s institutional knowledge and FDA clearance position it as a stable provider in an emerging market.